|
Session 44
Symposium
Frontiers in Vaccine Research
Wednesday, 4-6 pm
Room: Ballroom B/C |
| 4:00 pm 151 |
Advances in Vaccines Scaffolds
Bill Schief
Univ of Washington, Seatlle, US |
| 4:30 pm 152 |
Lessons Learned from HIV-1 Envelope Glycoprotein Immunogenicity Analysis
Mattias Forsell*1,2, B Dey1, A Moerner3, G Voss4, R Thorstensson3, P Kwong1, G Shaw5, J Mascola1, G Karlsson Hedestam2,3, and R Wyatt1
1Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US; 2Karolinska Inst, Stockholm, Sweden; 3Swedish Ctr for Infectious Disease Control, Solna; 4GlaxoSmithKline, Rixensart, Belgium; and 5Univ of Alabama at Birmingham, US |
| 5:00 pm 153 |
Identification and Characterization of Transmitted and Early Founder Viruses in Primary HIV-1 Infection
B Keele1, E Giorgi2,3, J Salazar-Gonzalez1, F Gao4, R Swanstrom5, M Busch6, B Haynes4, B Korber2,7, B Hahn1, and George Shaw*1
1Univ of Alabama at Birmingham, US; 2Los Alamos Natl Lab, NM, US; 3Univ of Massachusetts, Amherst, US; 4Duke Univ, Durham, NC, US; 5Univ of North Carolina at Chapel Hill, US; 6Blood Systems Res Inst, San Francisco, CA, US; and 7Santa Fe Inst, NM, US |
| 5:30 pm 154 |
Attenuated SIV Models and Protection from Pathogenic Heterologous Challenges
James Hoxie*1, A Jordan1, B Haggarty1, J Romano1, M Piatak2, J Lifson2, D Montefiori3, M Marsh4, and P Fultz5
1Univ of Pennsylvania, Philadelphia, US; 2NCI-Frederick, MD, US; 3Duke Univ, Durham, NC, US; 4Univ Coll London, UK; and 5Univ of Alabama at Birmingham, US |
|
